Ioannis Parodis

Articles in journals

• Gomez, A. , Walhelm, T. , Loeff, F. C. , Jönsen, A. , Nikolopoulos, D. , van den Broek, B. , Bengtsson, A. A. , de Vries, A. & et al. (2025). Belimumab concentrations and immunogenicity in relation to drug effectiveness and safety in SLE within a Swedish real-world setting.  Rheumatology. [BibTeX]
• Grosso, G. , Giannopoulou, N. , Tsoi, A. , Cetrez, N. , Nikolopoulos, D. , Lindblom, J. & Parodis, I. (2025). Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trials.  Rheumatology. [BibTeX]
• Hoff, L. S. , Parodis, I. , Gupta, L. & COVAD study group, -. (2025). Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: Results from the COVAD study.  Rheumatology, 64 (2), 597-606. [BibTeX]
• Ali, S. S. , Demetriou, C. , Parodis, I. , Tan, A. L. , Edgar Gracia-Ramos, A. , Joshi, M. , Caballero-Uribe, C. V. , Saha, S. & et al. (2025). Determinants of physical function, as measured using PROMIS PF-10a, in patients with rheumatoid arthritis: results from the international COVID-19 Vaccination in Autoimmune Diseases (COVAD) study.  Rheumatology: Advances in Practice, 9 (1). [BibTeX]
• Gomez, A. , Parodis, I. , Saleh, M. , Simard, J. F. , Sjöwall, C. & Arkema, E. V. (2025). Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from Sweden.  Lupus Science and Medicine, 12 (1). [BibTeX]
• Nikolopoulos, D. , Sentis, G. , Kitsios, I. , Garantziotis, P. , Kapsala, N. , Pieta, A. , Flouda, S. , Manolakou, T. & et al. (2025). Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus.  Annals of the Rheumatic Diseases. [BibTeX]
• Parodis, I. , Stephens, T. , Dominicus, A. , Eek, D. & Sjöwall, C. (2025). Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up.  Rheumatology, 64 (2), 639-647. [BibTeX]
• Lindblom, J. , Lagutkin, D. , Sherina, N. , Idborg, H. , Beretta, L. , Borghi, M. O. , Peyper, J. M. , Barturen, G. & et al. (2025). Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1.  Annals of the Rheumatic Diseases. [BibTeX]
• Parodis, I. , Lindblom, J. , Palazzo, L. , Cetrez, N. , Oon, S. , Ala, H. , van Vollenhoven, R. F. , Morand, E. & et al. (2025). Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.  RMD Open, 11 (2). [BibTeX]
• Botto, J. , Cetrez, N. , Nikolopoulos, D. , Regardt, M. , Heintz, E. , Lindblom, J. & Parodis, I. (2025). Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms.  Rheumatology: Advances in Practice, 9 (2). [BibTeX]
• Jägerback, S. , Gomez, A. & Parodis, I. (2025). Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab.  Rheumatology, 64 (2), 623-631. [BibTeX]
• Parodis, I. (2025). Promise and challenges of mesenchymal stromal cell therapy in severe SLE.  The Lancet Rheumatology, 7 (4), e224-e226. [BibTeX]
• Nielsen, W. , Parodis, I. , Touma, Z. & OMERACT SLE Working Group, -. (2025). Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set.  Seminars in Arthritis & Rheumatism, 72. [BibTeX]
• Shaharir, S. S. , Nawi, A. M. , Mariamutu, T. N. , Kamaruzaman, L. , Said, M. S. M. , Rajalingham, S. , Parodis, I. , Sarkar, M. & et al. (2025). Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study.  International journal of rheumatic diseases, 28 (1). [BibTeX]
• Fornaro, M. , Venerito, V. , Pellico, M. R. , Iannone, F. , Joshi, M. , Chen, Y. , Tan, A. L. , Saha, S. & et al. (2025). The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset.  Rheumatology, 64 (4), 2133-2142. [BibTeX]
• Gomez, A. , Lindblom, J. , Parodis, I. & Bertsias, G. (2025). Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomised clinical trials of belimumab.  Rheumatology. [BibTeX]
• Depascale, R. , Da Mutten, R. , Lindblom, J. , Cetrez, N. , Palazzo, L. , Iaccarino, L. , Doria, A. , Nikolopoulos, D. & et al. (2025). Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumab.  Rheumatology. [BibTeX]
• Borg, A. , Georg, C. , Jobs, B. , Huss, V. , Waldenlind, K. , Ruiz, M. , Edelbring, S. , Skantze, G. & et al. (2025). Virtual Patient Simulations Using Social Robotics Combined With Large Language Models for Clinical Reasoning Training in Medical Education: Mixed Methods Study.  Journal of Medical Internet Research, 27, e63312. [BibTeX]
• Parodis, I. , Lindblom, J. , Levy, R. A. , Zen, M. , Cetrez, N. , Gomez, A. , Oon, S. , Henning, C. & et al. (2024). Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.  The Lancet Rheumatology, 6 (11), e751-e761. [BibTeX]
• Gomez, A. , Jägerback, S. , Sjöwall, C. & Parodis, I. (2024). Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.  Rheumatology, 63 (2), 338-348. [BibTeX]
• Loeff, F. C. , Parodis, I. , Walhelm, T. , Jönsen, A. , Nikolopoulos, D. , Sjöwall, C. , Bengtsson, A. A. , Kos, D. & et al. (2024). Belimumab concentration measurements using a homologous anti-idiotype immunoassay.  JIM - Journal of Immunological Methods, 532. [BibTeX]
• Palazzo, L. , Lindblom, J. , Kihlgren Olsson, E. , Nikiphorou, E. , Wincup, C. , Saha, S. , Shaharir, S. S. , Katchamart, W. & et al. (2024). Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.  Rheumatology International, 44 (10), 1923-1933. [BibTeX]
• Triantafyllias, K. , Liverakos, S. , Muthuraman, M. , Cavagna, L. , Parodis, I. & Schwarting, A. (2024). Cardiovascular Risk Evaluation in Psoriatic Arthritis by Aortic Stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the Prospective PSOCARD Cohort Study.  Rheumatology and therapy, 11 (4), 897-911. [BibTeX]
• Shumnalieva, R. , Ravichandran, N. , Hannah, J. , Javaid, M. , Darooka, N. , Roy, D. , Gonzalez, D. E. , Velikova, T. & et al. (2024). Characteristics of emerging new autoimmune diseases after COVID-19 vaccination: A sub-study by the COVAD group.  International journal of rheumatic diseases, 27 (5). [BibTeX]
• Kadam, E. , Javaid, M. , Sen, P. , Saha, S. , Ziade, N. , Day, J. , Wincup, C. , Andreoli, L. & et al. (2024). Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies.  Rheumatology International, 44 (7), 1233-1244. [BibTeX]
• Ahmed, S. , Gupta, L. , Kuwana, M. , Pauling, J. D. , Day, J. , Ravichandran, N. , Joshi, M. , Parodis, I. & et al. (2024). Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey.  Rheumatology International, 44 (1), 89-97. [BibTeX]
• Panchawagh, S. , Ravichandran, N. , Barman, B. , Nune, A. , Javaid, M. , Gracia-Ramos, A. E. , Day, J. , Joshi, M. & et al. (2024). COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group.  Rheumatology International, 44 (1), 73-80. [BibTeX]
• Dey, M. , Doskaliuk, B. , Parodis, I. , Lindblom, J. , Wincup, C. , Joshi, M. , Dey, D. , Katchamart, W. & et al. (2024). COVID-19 vaccination-related delayed adverse events among people with rheumatoid arthritis: results from the international COVAD survey.  Rheumatology International, 44 (12), 2853-2861. [BibTeX]
• Andreoli, L. , Parodis, I. & Gupta, L. (2024). COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study.  Rheumatology, 63 (5), 1341-1351. [BibTeX]
• Palazzo, L. , Lindblom, J. , Çetrez, N. , Ala, H. & Parodis, I. (2024). Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab.  Rheumatology, 63 (3), 798-808. [BibTeX]
• Nikolopoulos, D. , Loukogiannaki, C. , Sentis, G. , Garantziotis, P. , Manolakou, T. , Kapsala, N. , Nikoloudaki, M. , Pieta, A. & et al. (2024). Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.  Annals of the Rheumatic Diseases, 83 (9), 1132-1143. [BibTeX]
• Enocsson, H. , Lundberg, I. E. , Herrmann, M. , Parodis, I. & Sjöwall, C. (2024). Editorial: Autoantibodies for diagnostics, prognostics, and surveillance in autoimmune disease.  Frontiers in Medicine, 11. [BibTeX]
• Parodis, I. (2024). Enhancing lupus outcomes by means of biology beyond overt clinical features, exemplified in an in-depth investigation of the effects of circadian rhythm disruption.  Lupus Science and Medicine, 11 (1). [BibTeX]
• Fanouriakis, A. , Kostopoulou, M. , Andersen, J. , Aringer, M. , Arnaud, L. , Bae, S. , Boletis, J. , Bruce, I. N. & et al. (2024). EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.  Annals of the Rheumatic Diseases, 83 (1), 15-29. [BibTeX]
• Parodis, I. , Girard-Guyonvarc'h, C. , Arnaud, L. , Distler, O. , Domján, A. , Van den Ende, C. H. M. , Fligelstone, K. , Kocher, A. & et al. (2024). EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.  Annals of the Rheumatic Diseases, 83, 720-729. [BibTeX]
• Emamikia, S. , Gomez, A. , Ådahl, T. , von Perner, G. , Enman, Y. , Chatzidionysiou, K. , Arkema, E. V. & Parodis, I. (2024). Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey.  Lupus, 33 (6), 615-628. [BibTeX]
• Walhelm, T. , Wirestam, L. , Enman, Y. , Parodis, I. & Sjöwall, C. (2024). Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral Centre.  Journal of Clinical Medicine, 13 (5). [BibTeX]
• Naveen, R. , Parodis, I. & Gupta, L. (2024). Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and 2 surveys.  Rheumatology, 63 (1), 127-139. [BibTeX]
• Sandhu, N. K. , Parodis, I. , Gupta, L. & COVAD Study Group, -. (2024). Flares of autoimmune rheumatic disease following COVID-19 infection: Observations from the COVAD study.  International journal of rheumatic diseases, 27 (1). [BibTeX]
• Yoshida, A. , Kim, M. , Kuwana, M. , Ravichandran, N. , Makol, A. , Sen, P. , Lilleker, J. B. , Agarwal, V. & et al. (2024). Gender differences in patient experience in idiopathic inflammatory myopathies: Sub analysis from the COVAD dataset.  Modern Rheumatology, 34 (4), 756-766. [BibTeX]
• Ziade, N. , Aoude, M. , Hmamouchi, I. , Naveen, R. , Lilleker, J. B. , Sen, P. , Joshi, M. , Agarwal, V. & et al. (2024). Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study.  Rheumatology, 63 (3), 657-664. [BibTeX]
• Parodis, I. & Sjöwall, C. (2024). Immune Mechanisms and Biomarkers in Systemic Lupus Erythematosus.  International Journal of Molecular Sciences, 25 (18). [BibTeX]
• Yoshida, A. , Li, Y. , Maroufy, V. , Kuwana, M. , Sazliyana Shaharir, S. , Makol, A. , Sen, P. , Lilleker, J. B. & et al. (2024). Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey.  Rheumatology: Advances in Practice, 8 (2). [BibTeX]
• Parodis, I. , Lindblom, J. , Toro-Domínguez, D. , Beretta, L. , Borghi, M. O. , Castillo, J. , Carnero-Montoro, E. , Enman, Y. & et al. (2024). Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis.  Kidney international reports, 9 (6), 1817-1835. [BibTeX]
• Santiago, T. , Fernandes, R. , Ferreira, R. , Parodis, I. & Bostrom, C. (2024). Lessons learnt from the recent recommendations for the non-pharmacological management of systemic sclerosis.  ARP rheumatology, 3 (2), 82-83. [BibTeX]
• Joshi, M. , Darooka, N. , Saha, S. , Dyball, S. , Sen, P. , Yaadav, P. , Javaid, M. , Kadam, E. & et al. (2024). Listening to patients, for the patients: The COVAD Study-Vision, organizational structure, and challenges.  International Journal of Rheumatic Diseases, 27 (5). [BibTeX]
• Parodis, I. , Lindblom, J. , Barturen, G. , Ortega-Castro, R. , Cervera, R. , Pers, J. , Genre, F. , Hiepe, F. & et al. (2024). Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.  Annals of the Rheumatic Diseases, 83 (7), 889-900. [BibTeX]
• Touma, Z. , Parodis, I. & Strand, V. (2024). More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus.  Journal of Rheumatology, 51 (1), 4-6. [BibTeX]
• Nikolopoulos, D. , Cetrez, N. , Lindblom, J. & Parodis, I. (2024). Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials.  Rheumatology International, 44 (9), 1679-1689. [BibTeX]
• Gomez, A. , Parodis, I. & Sjöwall, C. (2024). Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study.  Rheumatology International, 44 (5), 851-861. [BibTeX]
• Nielsen, W. , Strand, V. , Simon, L. S. , Parodis, I. , Kim, A. H. J. , Desai, M. , Enman, Y. , Wallace, D. & et al. (2024). OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set.  Seminars in Arthritis & Rheumatism, 65. [BibTeX]
• Nielsen, W. , Parodis, I. , Touma, Z. & OMERACT SLE Working Group, -. (2024). OMERACT systemic lupus erythematosus domain survey.  Seminars in Arthritis & Rheumatism, 68. [BibTeX]
• Nikolopoulos, D. , Cetrez, N. , Lindblom, J. , Palazzo, L. , Enman, Y. & Parodis, I. (2024). Patients with neuropsychiatric involvement systemic lupus erythematosus experience poorer health-related quality of life and more fatigue than systemic lupus erythematosus patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity.  Rheumatology, 63 (9), 2494-2502. [BibTeX]
• Parodis, I. , Gomez, A. , Lindblom, J. & Rovin, B. H. (2024). Response to Comment on "Effect of Belimumab on Preventing De Novo Renal Lupus Flares".  Kidney International Reports, 9 (10), 3077-3078. [BibTeX]
• Parodis, I. , Lindblom, J. , Tsoi, A. , Palazzo, L. , Sporre, K. B. , Enman, Y. , Nikolopoulos, D. & Beretta, L. (2024). Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab.  Rheumatology. [BibTeX]
• Chatterjee, T. , Ravichandran, N. , Nair, N. , Gracia-Ramos, A. E. , Barman, B. , Sen, P. , Joshi, M. , Saha, S. & et al. (2024). Type 1 diabetes, COVID-19 vaccines and short-term safety: Subgroup analysis from the global COVAD study.  Journal of Diabetes Investigation, 15 (1), 131-138. [BibTeX]
• Hoff, L. S. , Ravichandran, N. , Shinjo, S. K. , Day, J. , Sen, P. , Junior, J. G. , Lilleker, J. B. , Joshi, M. & et al. (2023). COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey.  Rheumatology International, 43 (1), 47-58. [BibTeX]
• R., N. , Parodis, I. , Joshi, M. , Sen, P. , Lindblom, J. , Agarwal, V. , Lilleker, J. B. , Tan, A. L. & et al. (2023). COVID-19 vaccination in autoimmune diseases (COVAD) Study: vaccine safety and tolerance in rheumatoid arthritis.  Rheumatology, 62 (7), 2366-2376. [BibTeX]
• Dey, M. , Doskaliuk, B. , Lindblom, J. , Nikiphorou, E. , Wincup, C. , Fathima, M. , Saha, S. , Shaharir, S. S. & et al. (2023). COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus.  Journal of Clinical Medicine, 12 (24). [BibTeX]
• Giannopoulou, N. , Gupta, L. , Andreoli, L. , Lini, D. , Nikiphorou, E. , Aggarwal, R. , Agarwal, V. , Parodis, I. & et al. (2023). COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus.  Autoimmunity Reviews, 22 (4). [BibTeX]
• Hege, I. , Adler, M. , Donath, D. , Durning, S. J. , Edelbring, S. , Elvén, M. , Bogusz, A. , Georg, C. & et al. (2023). Developing a European longitudinal and interprofessional curriculum for clinical reasoning.  Diagnosis (Berlin, Germany), 10 (3), 218-224. [BibTeX]
• Lindblom, J. , Toro-Domínguez, D. , Carnero-Montoro, E. , Beretta, L. , Borghi, M. O. , Castillo, J. , Enman, Y. , Mohan, C. & et al. (2023). Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus.  Journal of Autoimmunity, 136. [BibTeX]
• Parodis, I. , Lindblom, J. , Cetrez, N. , Palazzo, L. , Ala, H. , Houssiau, F. A. , Sjöwall, C. & Rovin, B. H. (2023). Effect of Belimumab on Preventing de novo Renal Lupus Flares.  Kidney international reports, 8 (9), 1822-1830. [BibTeX]
• Ali, S. S. , Parodis, I. , Gupta, L. & COVAD Study Group, -. (2023). Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study.  Rheumatology, 62 (9), e263-e268. [BibTeX]
• Jagtap, K. , Parodis, I. , Gupta, L. & COVAD study group, -. (2023). Flares in autoimmune rheumatic diseases in the post-COVID-19 vaccination period: A Cross-sequential study based on COVAD surveys.  Rheumatology, 62 (12), 3838-3848. [BibTeX]
• Grignaschi, S. , Kim, M. , Zanframundo, G. , Ravichandran, N. , Lilleker, J. B. , Sen, P. , Joshi, M. , Agarwal, V. & et al. (2023). High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey.  Rheumatology International, 43 (9), 1637-1649. [BibTeX]
• Dey, M. , Parodis, I. , Gupta, L. & COVAD Study Group, -. (2023). Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study.  Rheumatology, 62 (5), e147-e152. [BibTeX]
• Yoshida, A. , Kim, M. , Kuwana, M. , Naveen, R. , Makol, A. , Sen, P. , Lilleker, J. B. , Agarwal, V. & et al. (2023). Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey.  Rheumatology, 62 (3), 1204-1215. [BibTeX]
• Da Mutten, R. , Borg, A. , Chatzidionysiou, K. & Parodis, I. (2023). Intracardiac Thrombi in Morbus Adamantiades-Behçet in Two Swedish Patients.  Journal of Clinical Medicine, 12 (16). [BibTeX]
• Doskaliuk, B. , Parodis, I. , Gupta, L. & COVAD Study Group, -. (2023). Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.  Rheumatology International, 43 (9), 1651-1664. [BibTeX]
• Parodis, I. (2023). Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus.  The Lancet Rheumatology, 5 (1), E4-E6. [BibTeX]
• Borg, A. , Lindblom, J. , Gomez, A. , Soltani, A. , Enman, Y. , Heintz, E. , Regardt, M. , Grannas, D. & et al. (2023). Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus.  Frontiers in Medicine, 10. [BibTeX]
• Shinjo, S. K. , Kim, M. , Hoff, L. S. , Missé, R. G. , Sen, P. , Naveen, R. , Day, J. , Cordeiro, R. A. & et al. (2023). Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study.  International journal of rheumatic diseases, 26 (4), 727-739. [BibTeX]
• R., N. , Nikiphorou, E. , Joshi, M. , Sen, P. , Lindblom, J. , Agarwal, V. , Lilleker, J. B. , Tan, A. L. & et al. (2023). Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.  Rheumatology, 62 (7), 2453-2463. [BibTeX]
• Hua, N. , Gomez, A. , Lindblom, J. , Emamikia, S. , Enman, Y. , Grannas, D. , Heintz, E. , Regardt, M. & et al. (2023). Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State.  Rheumatology, 62 (12), 3916-3923. [BibTeX]
• Lindblom, J. , Beretta, L. , Borghi, M. O. , Alarcón-Riquelme, M. E. , Parodis, I. & PRECISESADS Clinical Consortium, -. (2023). Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus.  Frontiers in Immunology, 14. [BibTeX]
• Naveen, R. , Thakare, D. R. , Kuwana, M. , Pauling, J. D. , Day, J. , Joshi, M. , Parodis, I. , Sen, P. & et al. (2023). Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.  Rheumatology International, 43 (7), 1265-1275. [BibTeX]
• Sen, P. , Parodis, I. , Agarwal, V. , Aggarwal, R. , Gupta, L. & COVAD study group, -. (2023). Vaccine hesitancy decreases, long term concerns remain in myositis, rheumatic disease patients: A comparative analysis of the COVAD surveys.  Rheumatology, 62 (10), 3291-3301. [BibTeX]
• Parodis, I. , Gomez, A. , Lindblom, J. , Chow, J. W. , Sjöwall, C. , Sciascia, S. & Gatto, M. (2022). B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.  International Journal of Molecular Sciences, 23 (22). [BibTeX]
• Sjöwall, C. & Parodis, I. (2022). Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus.  Journal of Clinical Medicine, 11 (22). [BibTeX]
• Fazal, Z. Z. , Sen, P. , Joshi, M. , Ravichandran, N. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Kim, M. & et al. (2022). COVAD survey 2 long-term outcomes: unmet need and protocol.  Rheumatology International, 42 (12), 2151-2158. [BibTeX]
• Sen, P. , Gupta, L. , Lilleker, J. B. , Aggarwal, V. , Kardes, S. , Milchert, M. , Gheita, T. , Salim, B. & et al. (2022). COVID-19 vaccination in autoimmune disease (COVAD) survey protocol.  Rheumatology International, 42 (1), 23-29. [BibTeX]
• Gil-Vila, A. , Naveen, R. , Selva-O'Callaghan, A. , Sen, P. , Nune, A. , Gaur, P. S. , Gonzalez, R. A. , Lilleker, J. B. & et al. (2022). COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies.  Muscle and Nerve, 66 (4), 426-437. [BibTeX]
• Sen, P. , R., N. , Nune, A. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Kim, M. , Day, J. & et al. (2022). COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study.  Rheumatology, 62 (1), 65-76. [BibTeX]
• Parodis, I. , Gomez, A. , Chow, J. W. , Borg, A. , Lindblom, J. & Gatto, M. (2022). Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab.  Frontiers in Immunology, 13. [BibTeX]
• Parodis, I. , Gomez, A. , Lindblom, J. , Chow, J. W. , Doria, A. & Gatto, M. (2022). Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.  Frontiers in medicine, 9. [BibTeX]
• Sciascia, S. , Parodis, I. & Karim, M. Y. (2022). Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease.  Frontiers in Immunology, 13. [BibTeX]
• Lindblom, J. , Zetterberg, S. , Emamikia, S. , Borg, A. , von Perner, G. , Enman, Y. , Heintz, E. , Regardt, M. & et al. (2022). EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus.  Frontiers in Medicine, 9. [BibTeX]
• Parodis, I. & Houssiau, F. A. (2022). From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?.  Annals of the Rheumatic Diseases, 81 (1), 15-19. [BibTeX]
• Emamikia, S. , Gentline, C. , Enman, Y. & Parodis, I. (2022). How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study.  Journal of Clinical Medicine, 11 (7). [BibTeX]
• Emamikia, S. , Oon, S. , Gomez, A. , Lindblom, J. , Borg, A. , Enman, Y. , Morand, E. , Grannas, D. & et al. (2022). Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.  Rheumatology, 61 (12), 4752-4762. [BibTeX]
• Hernández-Breijo, B. , Parodis, I. , Novella-Navarro, M. , Martínez-Feito, A. , Navarro-Compán, V. , Díaz-Almirón, M. , Pascual-Salcedo, D. , Balsa, A. & et al. (2022). Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis.  Journal of Clinical Medicine, 11 (17). [BibTeX]
• Stamm, T. , Parodis, I. & Studenic, P. (2022). Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus.  The Lancet Rheumatology, 4 (3), E157-E159. [BibTeX]
• Parodis, I. , Tamirou, F. & Houssiau, F. A. (2022). Treat-to-Target in Lupus Nephritis: What is the Role of the Repeat Kidney Biopsy?.  Archivum Immunologiae et Therapiae Experimentalis, 70 (1). [BibTeX]
• Sen, P. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Milchert, M. , Gheita, T. , Salim, B. , Velikova, T. & et al. (2022). Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study.  Indian Journal of Rheumatology, 17 (2), 188-191. [BibTeX]
• Hernández-Breijo, B. , Navarro-Compán, V. , Plasencia-Rodríguez, C. , Parodis, I. , Gehin, J. E. , Martínez-Feito, A. , Novella-Navarro, M. , Mezcua, A. & et al. (2021). BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.  Scientific Reports, 11 (1). [BibTeX]
• Parodis, I. , Andersson, L. , Durning, S. J. , Hege, I. , Knez, J. , Kononowicz, A. A. , Lidskog, M. , Petreski, T. & et al. (2021). Clinical Reasoning Needs to Be Explicitly Addressed in Health Professions Curricula: Recommendations from a European Consortium.  International Journal of Environmental Research and Public Health, 18 (21). [BibTeX]

Articles, reviews/surveys

• Piga, M. , Parodis, I. , Touma, Z. , Legge, A. , Ugarte-Gil, M. F. , Hmamouchi, I. , Gómez Puerta, J. A. , Devilliers, H. & et al. (2025). Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: Consensus statements from an international task force.  Autoimmunity Reviews, 24 (5). [BibTeX]
• Parodis, I. , Wincup, C. , Touma, Z. , Andersen, J. , Strand, V. & Sjöwall, C. (2025). Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?.  RMD Open, 11 (1). [BibTeX]
• Parodis, I. , Cetrez, N. , Palazzo, L. , Alberton, V. , Anders, H. , Bajema, I. M. , Costedoat-Chalumeau, N. , Malvar, A. & et al. (2025). Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: A systematic literature review-based proposal.  Autoimmunity Reviews, 24 (7). [BibTeX]
• Tsoi, A. , Nikolopoulos, D. & Parodis, I. (2024). Advances in the pharmacological management of systemic lupus erythematosus.  Expert Opinion on Pharmacotherapy, 25 (6), 705-716. [BibTeX]
• Tsoi, A. , Gomez, A. , Boström, C. , Pezzella, D. , Chow, J. W. , Girard-Guyonvarc'h, C. , Stamm, T. , Arnaud, L. & et al. (2024). Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature.  Rheumatology International, 44 (5), 765-778. [BibTeX]
• Nikolopoulos, D. , Lourenço, M. H. , Depascale, R. , Triantafyllias, K. & Parodis, I. (2024). Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.  Mediterranean journal of rheumatology, 35 (Suppl 2), 328-341. [BibTeX]
• Parodis, I. , Moroni, G. , Calatroni, M. , Bellis, E. & Gatto, M. (2024). Is per-protocol kidney biopsy required in lupus nephritis?.  Autoimmunity Reviews, 23 (1). [BibTeX]
• Parodis, I. , Tsoi, A. , Gomez, A. , Chow, J. W. , Girard-Guyonvarc'h, C. , Stamm, T. & Boström, C. (2024). Lifestyle interventions in the management of systemic sclerosis: a systematic review of the literature.  Rheumatology: Advances in Practice, 8 (2). [BibTeX]
• Blaess, J. , Geneton, S. , Goepfert, T. , Appenzeller, S. , Bordier, G. , Davergne, T. , Fuentes, Y. , Haglo, H. & et al. (2024). Recommendations for physical activity and exercise in persons living with Systemic Lupus Erythematosus (SLE): consensus by an international task force.  RMD Open, 10 (2). [BibTeX]
• Parodis, I. , Lanata, C. , Nikolopoulos, D. , Blazer, A. & Yazdany, J. (2024). Reframing health disparities in SLE: A critical reassessment of racial and ethnic differences in lupus disease outcomes.  Baillière's Best Practice & Research: Clinical Rheumatology, 37 (4). [BibTeX]
• Parodis, I. , Depascale, R. , Doria, A. & Anders, H. (2024). When should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?.  Autoimmunity Reviews, 23 (1). [BibTeX]
• Parodis, I. , Long, X. , Karlsson, M. C. I. & Huang, X. (2023). B Cell Tolerance and Targeted Therapies in SLE.  Journal of Clinical Medicine, 12 (19). [BibTeX]
• Gomez, A. , Enman, Y. & Parodis, I. (2023). Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence.  Patient Related Outcome Measures, 14, 1-13. [BibTeX]
• Nikolopoulos, D. & Parodis, I. (2023). Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition.  Frontiers in Medicine, 10. [BibTeX]
• Parodis, I. , Gomez, A. , Tsoi, A. , Chow, J. W. , Pezzella, D. , Girard, C. , Stamm, T. A. & Boström, C. (2023). Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.  RMD Open, 9 (3). [BibTeX]
• Parodis, I. , Gatto, M. & Sjöwall, C. (2022). B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools.  Frontiers in Medicine, 9. [BibTeX]
• Lindblom, J. , Mohan, C. & Parodis, I. (2022). Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade.  Brain Sciences, 12 (2). [BibTeX]
• Palazzo, L. , Lindblom, J. , Mohan, C. & Parodis, I. (2022). Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.  Journal of Clinical Medicine, 11 (19). [BibTeX]
• Lindblom, J. , Mohan, C. & Parodis, I. (2022). Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights.  Current Opinion in Rheumatology, 34 (2), 139-149. [BibTeX]
• Sciascia, S. , Roccatello, D. , Radin, M. , Parodis, I. , Yazdany, J. , Pons-Estel, G. & Mosca, M. (2022). Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.  Nature Reviews Rheumatology, 18, 9-21. [BibTeX]
• Gomez, A. & Parodis, I. (2022). Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature.  Autoimmunity Reviews, 21 (11). [BibTeX]
• Parodis, I. & Studenic, P. (2022). Patient-Reported Outcomes in Systemic Lupus Erythematosus: Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring?.  Journal of clinical medicine, 11 (2). [BibTeX]
• Dey, M. , Parodis, I. & Nikiphorou, E. (2021). Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management.  Journal of clinical medicine, 10 (16). [BibTeX]

Conference papers

• Parodis, I. , Nikolopoulos, D. , Lindblom, J. , Beretta, L. , Cetrez, N. , Peyper, J. , Barturen, G. , Jakobsson, P. J. & et al. (2025). IGG AND IGA AUTOANTIBODIES AGAINST NOVEL ANTIGEN SPECIFICITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH DIFFERENTIAL UNDERLYING MECHANISMS HERALDING PROMISE FOR EARLY DIAGNOSIS. In:  Annals of the Rheumatic Diseases. Elsevier. [BibTeX]
• Parodis, I. , Nikolopoulos, D. , Lindblom, J. , Beretta, L. , Cetrez, N. , Peyper, J. , Barturen, G. , Jakobsson, P. J. & et al. (2025). NOVEL IGG AND IGA AUTOANTIBODIES DIFFERENTIATING SYSTEMIC LUPUS ERYTHEMATOSUS FROM PRIMARY SJÖGREN'S SYNDROME AND SYSTEMIC SCLEROSIS. In:  Annals of the Rheumatic Diseases. Elsevier. [BibTeX]
• Rivas-Torrubia, M. , Morell, M. , Makowska, Z. , Kageyama, J. , Buttgereit, A. , Lindblom, J. , Consortium, P. C. , Parodis, I. & et al. (2025). UTILITY OF MOUSE MODELS OF LUPUS FOR CLINICAL RESEARCH AND DRUG TESTING. In:  Annals of the Rheumatic Diseases. Elsevier. [BibTeX]
• Elfar, E. , Sukhija, G. , Bechman, K. , Saha, S. , Knitza, J. , Caballero, C. V. , Yaadav, P. , Dzifa, D. & et al. (2024). ACTIVE JOINT DISEASE, PAIN AND FATIGUE ALL STRONGLY ASSOCIATE WITH POOR MENTAL HEALTH IN AN INTERNATIONAL COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COVAD SURVEY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2024), Vienna, Austria, June 12-15, 2024. (pp. 1022-1024). Elsevier. [BibTeX]
• Leuchten, N. , Parodis, I. , Brinks, R. & Aringer, M. (2024). Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024. (pp. 1375-1376). John Wiley & Sons. [BibTeX]
• Nikolopoulos, D. , Sentis, G. , Kitsos, J. , Garantziotis, P. , Kapsala, N. , Pieta, A. , Nikoloudaki, M. , Manolakou, T. & et al. (2024). Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024. (pp. 4909-4910). John Wiley & Sons. [BibTeX]
• Garantziotis, P. , Parodis, I. , Bertsias, G. , Boumpas, D. & Schett, G. (2024). Comparing the Molecular Landscape of the CAR-T Cell and Rituximab Mediated Remission in Systemic Lupus Erythematosus. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024. (pp. 3582-3584). John Wiley & Sons. [BibTeX]
• Gomez, A. , Parodis, I. , Saleh, M. , Simard, J. , Sjöwall, C. & Arkema, E. (2024). EVALUATING ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS USING REGISTER DATA: A NATIONWIDE, POPULATION-BASED STUDY FROM SWEDEN. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2024), Vienna, Austria, June 12-15, 2024. Elsevier. [BibTeX]
• Parodis, I. , Nikolopoulos, D. , Lindblom, J. , Lagutkin, D. , Beretta, L. , Borghi, M. O. , Peyper, J. , Barturen, G. & et al. (2024). IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024. (pp. 3439-3440). John Wiley & Sons. [BibTeX]
• Lindblom, J. , Nikolopoulos, D. , Toro-Dominguez, D. , Carnero-Montoro, E. , Borghi, M. O. , Castillo, J. , Enman, Y. , Mohan, C. & et al. (2024). LYMPHOCYTE, NK CELL AND MITOCHONDRIAL GENE DYSREGULATION PATTERNS SEPARATE PATIENTS WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS INTO DISTINCT SUBGROUPS WITH DIFFERENTIAL ANTICIPATED RESPONSE TO TARGETED THERAPIES. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2024), Vienna, Austria, June 12-15, 2024. (pp. 207-208). Elsevier. [BibTeX]
• Parodis, I. , Lindblom, J. , Cetrez, N. , Palazzo, L. , Oon, S. , Ala, H. , Van Vollenhoven, R. F. , Morand, E. & et al. (2024). OUTCOMES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH INTRAVENOUS OR SUBCUTANEOUS BELIMUMAB: A POST-HOC EFFICACY META-ANALYSIS BY BICLA CRITERIA. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2024), Vienna, Austria, June 12-15, 2024. Elsevier. [BibTeX]
• Parodis, I. , Lindblom, J. , Cetrez, N. , Palazzo, L. , Ala, H. , Nikpour, M. , Levitsky, A. & Strand, V. (2024). POOR HEALTH-RELATED QUALITY OF LIFE DESPITE LOW DISEASE ACTIVITY OR REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2024), Vienna, Austria, June 12-15, 2024. (pp. 1011-1012). Elsevier. [BibTeX]
• Nielsen, W. , Kharouf, F. , Munoz-Grajales, C. , Thayaparan, A. , Anderson, M. , Simon, L. , Desai, M. , Parodis, I. & et al. (2024). Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024. (pp. 1325-1328). John Wiley & Sons. [BibTeX]
• Yaadav, P. , Pellico, M. R. , Russell, A. , Lanis, A. , Nikiphorou, E. , Parodis, I. , Saha, S. , Sarkar, M. & et al. (2024). Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024. (pp. 4192-4194). John Wiley & Sons. [BibTeX]
• Pellico, M. R. , Fornaro, M. , Venerito, V. , Day, J. , Makol, A. , Sen, P. , Kadam, E. , Chatterjee, T. & et al. (2024). THE IMPACT OF MENTAL HEALTH COMORBIDITIES ON QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A COVAD-2 STUDY. In:  Annals of the Rheumatic Diseases. Elsevier. [BibTeX]
• Parodis, I. , Lindblom, J. , Tsoi, A. , Nikolopoulos, D. & Beretta, L. (2024). Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2024, Washington, D.C., USA, November 14-19, 2024. (pp. 3050-3053). John Wiley & Sons. [BibTeX]
• Depascale, R. , Cetrez, N. , Lindblom, J. , Iaccarino, L. , Doria, A. , Nikoloupolos, D. , Gatto, M. & Parodis, I. (2024). UNSUPERVISED MACHINE LEARNING IDENTIFIES DISTINCT SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT ENDOTYPES BASED ON B CELL PHENOTYPING AND AUTOANTIBODY PROFILES WITH DIFFERENTIAL RESPONSE TO BELIMUMAB. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2024), Vienna, Austria, June 12-15, 2024. Elsevier. [BibTeX]
• Olsson, E. K. , Ravichandran, N. , Nikiphorou, E. , Lindblom, J. , Saha, S. , Shaharir, S. S. , Katchamart, W. , Goo, P. A. & et al. (2023). BREAKTHROUGH SARS-COV-2 INFECTION IN FULLY VACCINATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASE (COVAD) STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 540-541). HighWire Press. [BibTeX]
• Gupta, L. , Ravichandran, N. , Venerito, V. , Dey, M. , Sen, P. , Saha, S. , Tan, A. L. , Shinjo, S. K. & et al. (2023). COMORBIDITIES, COMPLEX MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES AMONGAUTOIMMUNE RHEUMATIC DISEASES: DATA FROM THE COVAD STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 555-556). HighWire Press. [BibTeX]
• Andreoli, L. , Lini, D. , Schreiber, K. , Sen, P. , Ravichandran, N. , Parodis, I. , Toro Gutierrez, C. E. , Katchamart, W. & et al. (2023). COVID-19 VACCINE SAFETY DURING PREGNANCY AND BREASTFEEDING IN WOMEN WITH AUTOIMMUNE DISEASES: RESULTS FROM THE COVAD STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 56-57). HighWire Press. [BibTeX]
• Giannopoulou, N. , Gupta, L. , Andreoli, L. , Lini, D. , Nikiphorou, E. , Aggarwal, R. , Agarwal, V. & Parodis, I. (2023). COVID-19 VACCINE SAFETY DURING PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 1495-1496). HighWire Press. [BibTeX]
• Parodis, I. , Lindblom, J. , Çetrez, N. , Palazzo, L. , Ala, H. , Houssiau, F. , Sjöwall, C. & Rovin, B. (2023). De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab: Implications for revisiting belimumab dose. In:  Scandinavian Journal of Rheumatology. Paper presented at 39th Scandinavian Congress of Rheumatology, Copenhagen, Denmark, August 23-26, 2023. (pp. 46-46). Taylor & Francis. [BibTeX]
• Palazzo, L. , Lindblom, J. , Cetrez, N. , Ala, H. & Parodis, I. (2023). Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase Ill clinical trials of belimumab. In:  Scandinavian Journal of Rheumatology. Paper presented at 39th Scandinavian Congress of Rheumatology, Copenhagen, Denmark, August 23-26, 2023. (pp. 45-45). Taylor & Francis. [BibTeX]
• Holloway, A. , Lee, S. Y. , Nikiphorou, E. , Parodis, I. , Ravichandran, N. , Day, J. , Joshi, M. , Saha, S. & et al. (2023). EVALUATING GLOBAL PATTERNS IN TREATMENT AND PREVALENCE OF COMORBIDITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 1456-1458). HighWire Press. [BibTeX]
• Walhelm, T. , Wirestam, L. , Enman, Y. , Parodis, I. & Sjowall, C. (2023). FACTORS ASSOCIATED WITH SURVIVAL AND DISCONTINUATION OF ANTIMALARIAL AGENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A SWEDISH LONGITUDINAL REGISTRY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 902-903). HighWire Press. [BibTeX]
• Gupta, L. , Naveen, R. , Griger, Z. , Agarwal, V. , Sen, P. , Joshi, M. , Saha, S. , Jagtap, K. & et al. (2023). FLARES FOLLOWING COVID-19 VACCINATION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: COMBINED ANALYSIS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDIES. In:  Rheumatology. Paper presented at British Society for Rheumatology Annual Conference (BSR 2023), Manchester, UK, April 24-26, 2023. Oxford University Press. [BibTeX]
• Lee, S. Y. , Holloway, A. , Nikiphorou, E. , Parodis, I. , Ravichandran, N. , Day, J. , Joshi, M. , Saha, S. & et al. (2023). IDENTIFYING DETERMINANTS OF FAVOURABLE AND POOR PHYSICAL FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL COLLABORATIVE STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 1110-1112). HighWire Press. [BibTeX]
• Yoshida, A. , Li, Y. , Maroufy, V. , Kuwana, M. , Ravichandran, N. , Makol, A. , Sen, P. , Lilleker, J. B. & et al. (2023). IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A CROSS-SECTIONAL ANALYSIS FROM AN INTERNATIONAL SURVEY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 952-953). HighWire Press. [BibTeX]
• Gomez, A. , Jägerback, S. , Sjowall, C. & Parodis, I. (2023). LOW-DOSE BELIMUMAB AND ANTIMALARIAL AGENTS PREVENT RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FOUR RANDOMISED CLINICAL TRIALS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 1467-1468). HighWire Press. [BibTeX]
• Fornaro, M. , Venerito, V. , Iannone, F. , Ravichandran, N. , Nikiphorou, E. , Joshi, M. , Tan, A. L. , Saha, S. & et al. (2023). MULTIMORBIDITY AND PROMIS HEALTH OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM A LARGE, GLOBAL E-SURVEY (COVAD STUDY). In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 942-943). HighWire Press. [BibTeX]
• Sen, P. , Parodis, I. & Gupta, L. (2023). POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVAD STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 375-376). HighWire Press. [BibTeX]
• Gupta, L. , Sen, P. , Naveen, R. , Joshi, M. , Saha, S. , Jagtap, K. , Agarwal, V. , Distler, O. & et al. (2023). POST COVID-19 SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY. In:  Rheumatology. Paper presented at British Society for Rheumatology Annual Conference (BSR 2023), Manchester, UK, April 24-26, 2023. Oxford University Press. [BibTeX]
• Parodis, I. , Lindblom, J. , Cetrez, N. , Palazzo, L. , Ala, H. , Houssiau, F. , Sjowall, C. & Rovin, B. H. (2023). PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS - TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE?: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 909-910). HighWire Press. [BibTeX]
• Palazzo, L. , Lindblom, J. , Cetrez, N. , Ala, H. & Parodis, I. (2023). PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 1088-1088). HighWire Press. [BibTeX]
• Jägerback, S. , Gomez, A. & Parodis, I. (2023). PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 34-34). HighWire Press. [BibTeX]
• Ravichandran, N. , Parodis, I. , Gupta, L. , Katsuyuki Shinjo, S. , Ziade, N. , Milchert, M. , Cavagna, L. , Tan, A. L. & et al. (2023). PREVALENCE, CHARACTERISTICS, AND PREDICTORS OF BREAKTHROUGH COVID-19 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASE (COVAD) STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology, (EULAR 2023), Milan, Italy, May 31 - June 3, 2023. (pp. 56-56). HighWire Press. [BibTeX]
• Emamikia, S. , Gentline, C. , Enman, Y. & Parodis, I. (2022). CAN WE ENHANCE ADHERENCE TO MEDICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? RESULTS FROM A QUALITATIVE STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 439-439). HighWire Press. [BibTeX]
• Gupta, L. , Hoff, L. S. , R, N. , Sen, P. , Katsuyuki Shinjo, S. , Day, J. , Lilleker, J. B. , Agarwal, V. & et al. (2022). COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY.. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 334-336). HighWire Press. [BibTeX]
• Sen, P. , R, N. , Nune, A. , Lilleker, J. B. , Agarwal, V. , Kardes, S. , Kim, M. , Day, J. & et al. (2022). COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 966-967). HighWire Press. [BibTeX]
• Parodis, I. , Lindblom, J. , Toro-Dominguez, D. , Borghi, M. O. , Enman, Y. , Repsilber, D. , Mohan, C. , Alarcon-Riquelme, M. & et al. (2022). DRUG REPURPOSING FOR TREATING LUPUS NEPHRITIS BASED ON TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 326-326). HighWire Press. [BibTeX]
• Grignaschi, S. , Cavagna, L. , Kim, M. , R, N. , Lilleker, J. B. , Sen, P. , Agarwal, V. , Kardes, S. & et al. (2022). HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 748-748). HighWire Press. [BibTeX]
• Yoshida, A. , Kim, M. , Kuwana, M. , R, N. , Lilleker, J. B. , Sen, P. , Agarwal, V. , Kardes, S. & et al. (2022). IMPAIRED PROMIS PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS: RESULTS FROM THE MULTICENTER COVAD PATIENT REPORTED E-SURVEY. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 720-722). HighWire Press. [BibTeX]
• Gomez, A. , Parodis, I. & Sjöwall, C. (2022). OBESITY AND TOBACCO SMOKING ARE INDEPENDENTLY ASSOCIATED WITH POOR PATIENT-REPORTED OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A SWEDISH TERTIARY REFERRAL CENTRE. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 1402-1402). HighWire Press. [BibTeX]
• Parodis, I. , Gomez, A. , Tsoi, A. , Chow, J. W. , Pezzella, D. , Girard, C. , Stamm, T. , Boström, C. & et al. (2022). SYSTEMATIC LITERATURE REVIEW TO INFORM THE EULAR TASK FORCE FOR RECOMMENDATIONS/POINTS TO CONSIDER FOR THE NON-PHARMACOLOGICAL MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SYSTEMIC SCLEROSIS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 1098-1099). HighWire Press. [BibTeX]
• Lindblom, J. , Toro-Dominguez, D. , Borghi, M. O. , Iacobaeus, E. , Enman, Y. , Repsilber, D. , Mohan, C. , Alarcon-Riquelme, M. & et al. (2022). TRANSCRIPTOME PROFILING AND AUTOIMMUNITY-RELATED SEROLOGICAL MARKERS IDENTIFY TP53 AND C3AR AS DRUG TARGETS IN NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 326-326). HighWire Press. [BibTeX]
• Aoude, M. , Gupta, L. , Hmamouchi, I. , Grignaschi, S. , Cavagna, L. , Kim, M. , R, N. , Lilleker, J. B. & et al. (2022). TREATMENT PATTERNS OF IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM AN INTERNATIONAL COHORT OF OVER 1,400 PATIENTS. In:  Annals of the Rheumatic Diseases. Paper presented at European Congress of Rheumatology (EULAR 2022), Copenhagen, Denmark, June 1-4, 2022. (pp. 105-106). HighWire Press. [BibTeX]
• Parodis, I. , Gomez, A. , Lindblom, J. , Borg, A. , Emamikia, S. & Gatto, M. (2021). Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus: Results from Three Phase III Trials of Belimumab. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2021, (Virtual conference), November 5-9, 2021. (pp. 2699-2700). John Wiley & Sons. [BibTeX]
• Parodis, I. , Gomez, A. , Lindblom, J. , Borg, A. , Emamikia, S. & Gatto, M. (2021). Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2021, (Virtual conference), November 5-9, 2021. (pp. 2695-2696). John Wiley & Sons. [BibTeX]
• Hernandez-Breijo, B. , Parodis, I. , Plasencia-Rodríguez, C. , Díaz-Almirón, M. , Martínez-Feito, A. , Novella-Navarro, M. , Pascual-Salcedo, D. & Balsa, A. (2021). Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis. In:  Arthritis & Rheumatology. Paper presented at ACR Convergence 2021, (Virtual conference), November 5-9, 2021. (pp. 2586-2588). John Wiley & Sons. [BibTeX]
• Emamikia, S. , Oon, S. , Gomez, A. , Lindblom, J. , Borg, A. , Enman, Y. , Morand, E. , Grannas, D. & et al. (2021). The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus. In:  Arthritis & Rheumatology. John Wiley & Sons. [BibTeX]